Nothing Special   »   [go: up one dir, main page]

Gamal El-Din Mahmoud et al., 2021 - Google Patents

First-trimester neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as indicators for early diagnosis of preeclampsia

Gamal El-Din Mahmoud et al., 2021

View HTML
Document ID
14641943416777560733
Author
Gamal El-Din Mahmoud A
Ali Mohamed M
Ahmed El-Desouky E
Saad El-Din Radwan M
Publication year
Publication venue
Al-Azhar Medical Journal

External Links

Snippet

Background: Preeclampsia is a popular obstetric complication. Neutrophil to lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) have gained notable attention as systemic inflammatory response indicators in diverse clinical settings. Objective: To evaluate the …
Continue reading at journals.ekb.eg (HTML) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875—Nucleoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/574—Immunoassay; Biospecific binding assay for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/88—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving prostaglandins or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors

Similar Documents

Publication Publication Date Title
Yücel et al. Neutrophil to lymphocyte ratio, platelet to lymphocyte ratio, mean platelet volume, red cell distribution width and plateletcrit in preeclampsia
Kunze et al. Cytokines in noninvasively obtained amniotic fluid as predictors of fetal inflammatory response syndrome
EP2422202B1 (en) Methods for determining maternal health risks
Tarca et al. Prediction of preeclampsia throughout gestation with maternal characteristics and biophysical and biochemical markers: a longitudinal study
Heimberger et al. Angiogenic factor abnormalities and risk of peripartum complications and prematurity among urban predominantly obese parturients with chronic hypertension
Karapetian et al. Cell-free foetal DNA as a useful marker for preeclampsia prediction
Shinar et al. Placental growth factor as a diagnostic tool for placental mediated fetal growth restriction
Tun et al. Comparison of 12-hour urine protein and protein: creatinine ratio with 24-hour urine protein for the diagnosis of preeclampsia
Kumar et al. Role of sFLT-1/PlGF ratio in predicting severe adverse materno-fetal outcome in high risk women
Usta et al. Does the fibrinogen/albumin ratio predict the prognosis of pregnancies with abortus imminens?
Kong et al. Predicting chorioamnionitis in patients with preterm premature rupture of membranes using inflammatory indexes: a retrospective study
Alfandari et al. Easily generated hematological biomarkers and prediction of placental abruption
Gamal El-Din Mahmoud et al. First-trimester neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as indicators for early diagnosis of preeclampsia
EA024188B1 (en) HbF AND A1M AS EARLY STAGE MARKERS FOR PREECLAMPSIA
Gharib et al. Predictive value of maternal serum C-reactive protein levels with severity of preeclampsia
Njoroge et al. The interval between births and the risk of recurrent preeclampsia among predominantly high risk women in urban tertiary care center
Ananth et al. Acute placental abruption: Pathophysiology, clinical features, diagnosis, and consequences
Kumar et al. Correlation of sFlt/PlGF ratio with severity of preeclampsia in an Indian population
Tussupkaliyev et al. Urinary placental growth factor determined in the first trimester of pregnancy as a predictor of preeclampsia
Arenas et al. Use of the angiogenic biomarker profile to risk stratify patients with fetal growth restriction
Baser et al. Can Inflammatory Hematological Parameters be a Guide to Late-onset Fetal Growth Restriction?
Nuralievna et al. Management of the Reatening Preterm Birth
Bhalerao et al. A study protocol of maternal serum anti-mullerian hormone levels in antenatal women as predictor of preeclampsia
Hassanin et al. Predictive Value Of Placental Growth Factor In Preeclampsia
Özkan et al. Evaluation of Neutrophil/Lymphocyte and Thrombocyte/Lymphocyte Ratios in Cases of Preterm Premature Rupture of Membranes